HOCHBERGERSTRASSE

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

Retrieved on: 
Tuesday, May 7, 2024
Public, University, GSK plc, Investment, Health, Bacteria, Partnership, Research, Ethionamide, Pasteur Institute, Disease, GSK, Patient, CHF, Acinetobacter baumannii, MDR, TB, Series, Tuberculosis, Pharmaceutical industry

The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).

Key Points: 
  • The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).
  • As part of the expanded collaboration, GSK will take an equity stake in BioVersys' latest investment round.
  • Adding to further investments from existing and new investors, this extends the Series C financing by CHF 12.3 million, resulting in total proceeds of CHF 44.9 million for the Series C round to date.
  • Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys: "We are very pleased to announce both the expansion of our highly successful strategic collaboration with GSK and our partner’s participation in our latest financing round.

MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment

Retrieved on: 
Monday, October 3, 2022
Cancer, Hospital, Achievement, National, NCI, Neoplasm, Technology, Immunotherapy, Anderson, Research, MD, Education, Monroe Dunaway Anderson, Lung cancer, Radiation therapy, U.S. News & World Report, Biopsy, MD Anderson Cancer Center, Cell, P30, Patient, National Cancer Institute, Diagnosis, University, AFM, GLOBE, News, Medical imaging, Pharmaceutical industry

MD Anderson clinicians will lead validation and proof-of-concept studies to evaluate the ARTIDIS technology as a tool for predicting response to treatment in multiple solid tumor indications.

Key Points: 
  • MD Anderson clinicians will lead validation and proof-of-concept studies to evaluate the ARTIDIS technology as a tool for predicting response to treatment in multiple solid tumor indications.
  • The strategic alliance with MD Anderson builds on a previous sponsored research agreement with James Welsh, M.D., professor of Radiation Oncology at MD Anderson, focusing on understanding immunotherapy resistance and response [1].
  • Additionally, ARTIDIS has shown that nanomechanical alteration in cancer tissue is a potentially suitable marker for cancer aggressiveness and indicator of treatment response.
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).